New stock news | Smead announced listing on the Hong Kong Stock Exchange, covering the top three semiconductor silicon wafer factories and the top three packaging and testing factories.
According to the disclosure by the Hong Kong Stock Exchange on September 19th, Cyberport Information Technology Group Limited (referred to as Cyberport) has submitted an application for listing on the Main Board of the Hong Kong Stock Exchange.
According to the disclosure by the Hong Kong Stock Exchange on September 19, Simic Information Group Limited (referred to as Simic) has submitted its listing application to the Main Board of the Hong Kong Stock Exchange, with HAITONG INT'L, CITIC SEC, and China Securities Co., Ltd. International as joint sponsors.
According to the prospectus, Simic is a leading Chinese provider of intelligent industrial software solutions. With proprietary technology and independent intellectual property rights, the company has created the industry's first and only full-stack intelligent manufacturing and operational management software solution. Based on information from Zokuri Consulting, the company is the largest Chinese provider in the market for advanced industrial intelligent manufacturing software in China according to the industrial software revenue projection for 2024. According to the same source, among the top ten Chinese intelligent manufacturing software companies in terms of advanced industry revenue in 2024, the company also has the fastest compound annual growth rate in revenue from 2022 to 2024.
As per the information from Zokuri Consulting, as of June 30, 2025, the company has a customer base of 758 companies, covering six of the top eight wafer fabs in China, the top three silicon wafer manufacturers, and the top three assembly and testing facilities.
In terms of finances, for the fiscal years 2022, 2023, 2024, and the six months ending June 30, 2025, the company achieved revenues of approximately 181 million, 287 million, 499.7 million, and 283 million RMB respectively. During the same periods, the annual/periodic profits were approximately -80.91 million, 24.56 million, 73.83 million, and 33.62 million RMB respectively.
Related Articles

Merck & Co., Inc. (MRK.US) received FDA approval to market its K drug in subcutaneous injection form.

Founder: The end of the year is often an important time for market changes. Industries with higher profit margins are more likely to experience a reversal.

Price 818,000 yuan. NIO (09866) ET9 Horizon Special Edition officially launched.
Merck & Co., Inc. (MRK.US) received FDA approval to market its K drug in subcutaneous injection form.

Founder: The end of the year is often an important time for market changes. Industries with higher profit margins are more likely to experience a reversal.

Price 818,000 yuan. NIO (09866) ET9 Horizon Special Edition officially launched.

RECOMMEND

Three-Year R&D Spend Drains RMB 2.4 Billion, Urgent Cash Needs Drive Maiwei Biotech Back to Hong Kong Amid Compliance Scrutiny
18/09/2025

Why Generating Profit Remains Challenging for Lidar Companies
18/09/2025

SEC Adopts Landmark Rule to Restrict Shareholder Class Actions in Bid to Revive IPO Market
18/09/2025